Adjusted versus actual body weight dosing of 4-factor prothrombin complex concentrate in obese patients with...

Area of Science:

• Pharmacology
• Critical Care Medicine
• Hematology

Background:

• The standard dosing for 4-factor prothrombin complex concentrate (4F-PCC) is weight-based, with a 100 kg cap.
• Obese patients represent a unique challenge for 4F-PCC dosing due to a lack of specific guidelines.
• Previous studies have not adequately addressed optimal 4F-PCC dosing strategies in obesity.

Purpose of the Study:

• To compare the efficacy of 4F-PCC dosing based on actual body weight (ActBW) versus adjusted body weight (AdjBW) in obese patients.
• To determine the optimal dosing strategy for 4F-PCC in patients with a body mass index (BMI) of 30 kg/m² or higher.
• To evaluate the rate of coagulopathy reversal in obese patients receiving 4F-PCC.

Main Methods:

• A retrospective analysis of 78 obese patients (BMI ≥ 30 kg/m²) who received 4F-PCC for warfarin-associated bleeding reversal.
• Patients were divided into two groups: those dosed using AdjBW and those dosed using ActBW.
• The primary outcome was the percentage of patients achieving a post-treatment INR < 1.4 (neurologic indications) or < 1.5 (other indications).

Main Results:

• The AdjBW group had a significantly lower rate of achieving the goal INR compared to the ActBW group (36% vs. 68%; p=0.006).
• The median dose of 4F-PCC was lower in the AdjBW group (2120 units) compared to the ActBW group (2500 units; p=0.02).
• While not statistically significant, a higher proportion of patients in the ActBW group had intracranial hemorrhage (54% vs. 32%).

Conclusions:

• Dosing 4F-PCC using adjusted body weight in obese patients resulted in a significantly lower rate of coagulopathy reversal.
• Actual body weight dosing should be considered for obese patients when utilizing the 100 kg dose cap as per package insert recommendations.
• Further prospective studies are warranted to confirm optimal 4F-PCC dosing in obese populations.